

Sunflower Mannose Binding Lectin-Associated Serine Protease Inhibitor-1 (SFMI-1) and -2: Significant Inhibitors of Mannose Binding Lectin Pathway Which Helps in Multiple Sclerosis Treatment



Pouya Ghaderi^{1,2*}, Hamed Delfaraz^{1,2}, Mohaddese Ahmadabadi^{1,2} and Mahdiye Ehsani^{1,2}

¹Student Research Committee, Mashhad Islamic Azad University, Iran

²Mashhad Neuroscience Research Group, Iran

Submission: December 03, 2017; **Published:** December 11, 2017

***Corresponding author:** Pouya Ghaderi, Student Research Committee, School of Medicine, Mashhad Islamic Azad University, Mashhad, Iran, Email: Pouyaghaderi73@gmail.com

Keywords: Mannose binding lectin; Mannose binding lectin-associated serine protease (MASP); Multiple sclerosis; Sunflower mannose binding lectin-associated serine protease inhibitor (SMFI)

Opinion

One of the important parts of innate immunity is complement system that occurs in three different ways; the classic, the alternative and the lectin pathway. The four pattern recognition molecules that have been identified till now are Mannose binding lectin (MBL), a component of lectin pathway, and three ficolins (ficolin1,-2 and -3) which compound to the carbohydrates of the cell surface. MBL associated serine protease1 (MASP-1), MASP-2 and -3 are three proteases which associate with recognition molecules. Also MBL-associated protein 19 and MBL-associated protein 44 are two non-catalytic molecules that their role is association with recognition molecules. MASP-1 and MASP-2 activate the lectin pathway but function of MASP-3 is unclear. Although some researches show that MASP-3 down regulate activation of two other MASPs and has a similar role like MBL-association 19 and MBL-association 44 that they inhibit MBL pathway too.

Researches show that MBL pathway has a critical role in pathogenesis of autoimmune diseases such as multiple sclerosis (MS). Researches indicate that levels of MBL pathway activator components (MASP-1 and MASP-2) are higher in serum plasma of MS patients.

So inhibiting activators of MBL pathway seems to be useful for MS treatment and reducing its disabilities.

Sunflower MASP inhibitor-1 (SFMI-1) and sunflower MASP inhibitor-2 (SFMI-2) are two peptides with 14 amino acids that inhibit MASP-1 and MASP-2 and block the lectin pathway activation. This article suggests using SFMI-1 and SFMI-2 in drugs to targeted therapy of MS and decreasing its symptoms.



This work is licensed under Creative Commons Attribution 4.0 License
DOI: [10.19080/JOJS.2019.02.555596](https://doi.org/10.19080/JOJS.2019.02.555596)

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
(Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission

<https://juniperpublishers.com/online-submission.php>